Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7951 to 7965 of 8905 results

  1. Ocriplasmin for treating vitreomacular traction (TA297)

    We have withdrawn this guidance. Inceptua has stopped marketing Ocriplasmin (Jetrea) and its marketing authorisation has been withdrawn.

    Withdrawn guidance

  2. Bosutinib for previously treated chronic myeloid leukaemia (TA299)

    This guidance has been updated and replaced by NICE technology appraisal guidance 401. 

    Withdrawn guidance

  3. Ovarian cancer - taxanes (TA3)

    This guidance has been replaced by NICE technology appraisal guidance 55. 

    Withdrawn guidance

  4. Ovarian cancer - topotecan (TA28)

    This guidance has been replaced by NICE technology appraisal guidance 91.

    Withdrawn guidance

  5. Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (TA280)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Withdrawn guidance

  6. Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal) (TA281)

    This guidance has been updated and replaced by NICE guideline NG219.

    Withdrawn guidance

  7. Pirfenidone for treating idiopathic pulmonary fibrosis (TA282)

    This guidance has been updated and replaced by NICE technology appraisal guidance 504.

    Withdrawn guidance

  8. Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (TA289)

    This guidance has been updated and replaced by NICE technology appraisal guidance 386.

    Withdrawn guidance

  9. Pegloticase for treating severe debilitating chronic tophaceous gout (TA291)

    The guidance has been withdrawn because pegloticase (Krystexxa) no longer has a marketing authorisation. See the European Medicines Agency product information.

    Withdrawn guidance

  10. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)

    This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.

    Withdrawn guidance

  11. Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy (TA271)

    This guidance has been updated and replaced by NICE technology appraisal guidance 301.

    Withdrawn guidance

  12. Familial breast cancer (CG14)

    This guidance has been updated and replaced by NICE guideline CG41.

    Withdrawn guideline

  13. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (CG144)

    This guidance has been updated and replaced by NICE guideline NG158.

    Withdrawn guideline

  14. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

    This guidance has been updated and replaced by NICE highly specialised technologies guidance 23.

    Withdrawn guidance

  15. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)

    This guidance has been updated and replaced by NICE highly specialised technologies guidance 22.

    Withdrawn guidance